Pfizer 2011 Annual Report Download - page 113

Download and view the complete annual report

Please find page 113 of the 2011 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 117

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Significant Product Revenues
Significant product revenues follow:
YEAR ENDED DECEMBER 31,
(MILLIONS OF DOLLARS) 2011 2010 2009
Revenues from biopharmaceutical products(a):
Lipitor(b) $ 9,577 $10,733 $11,434
Lyrica 3,693 3,063 2,840
Prevnar 13/Prevenar 13(c) 3,657 2,416 —
Enbrel (Outside the U.S. and Canada)(c) 3,666 3,274 378
Celebrex 2,523 2,374 2,383
Viagra 1,981 1,928 1,892
Norvasc 1,445 1,506 1,973
Zyvox 1,283 1,176 1,141
Xalatan/Xalacom 1,250 1,749 1,737
Sutent 1,187 1,066 964
Geodon/Zeldox 1,022 1,027 1,002
Premarin family(c) 1,013 1,040 213
Genotropin 889 885 887
Detrol/Detrol LA 883 1,013 1,154
Vfend 747 825 798
Chantix/Champix 720 755 700
BeneFIX(c) 693 643 98
Effexor(c) 678 1,718 520
Zosyn/Tazocin(c) 636 952 184
Pristiq(c) 577 466 82
Zoloft 573 532 516
Caduet 538 527 548
Revatio 535 481 450
Medrol 510 455 457
ReFacto AF/Xyntha(c) 506 404 47
Prevnar/Prevenar (7-valent)(c) 488 1,253 287
Zithromax/Zmax 453 415 430
Aricept(d) 450 454 435
Fragmin 382 341 359
Cardura 380 413 457
Rapamune(c) 372 388 57
Aromasin 361 483 483
BMP2(c) 340 400 81
Relpax 341 323 326
Xanax XR 306 307 318
Tygacil(c) 298 324 54
Neurontin 289 322 327
Diflucan 265 278 281
Arthrotec 242 250 270
Unasyn 231 244 245
Sulperazon 218 213 204
Skelaxin(e) 203 ——
Inspra 195 157 130
Dalacin/Cleocin 192 214 241
Methotrexate 191 164 21
Toviaz 187 137 59
Somavert 183 157 147
Alliance revenues(f) 3,630 4,084 2,925
All other biopharmaceutical products(g) 6,768 6,194 4,913
Total revenues from biopharmaceutical products 57,747 58,523 45,448
Revenues from other products(a):
Animal Health(g) 4,184 3,575 2,764
Consumer Healthcare(c) 3,057 2,772 494
Nutrition(c) 2,138 1,867 191
Pfizer CentreSource 299 320 372
Total revenues(a) $67,425 $67,057 $49,269
(a) For 2011, includes King commencing on the acquisition date of January 31, 2011. For 2009, includes Wyeth commencing on the acquisition date of
October 15, 2009.
(b) On November 30, 2011, Lipitor lost exclusivity in the U.S. This loss of exclusivity reduced revenues by $326 million in 2011, in comparison with
2010.
(c) Acquired from Wyeth.
(d) Represents direct sales under license agreement with Eisai Co., Ltd.
(e) Acquired from King.
(f) Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif and Spiriva.
(g) Includes products from legacy Pfizer, legacy Wyeth and legacy King.
112 2011 Financial Report